Focused On-demand Library for Kinesin-like protein KIF23

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

Q02241

UPID:

KIF23_HUMAN

Alternative names:

Kinesin-like protein 5; Mitotic kinesin-like protein 1

Alternative UPACC:

Q02241; B4E1K0; Q8WVP0

Background:

Kinesin-like protein KIF23, also known as Mitotic kinesin-like protein 1, plays a pivotal role in cell division. It is a key component of the centralspindlin complex, essential for cytokinesis and Rho-mediated signaling. KIF23's activity involves moving antiparallel microtubules and is crucial for the formation of the myosin contractile ring during cell cycle cytokinesis.

Therapeutic significance:

KIF23 is linked to Anemia, congenital dyserythropoietic, 3A, a disorder marked by ineffective erythropoiesis and hemolytic anemia. Targeting KIF23's function or its pathways could offer novel therapeutic approaches for treating this blood disorder.